Treatment of behavior disorders in mental retardation: Report on transitioning to atypical antipsychotics, with an emphasis on risperidone

Journal of Clinical Psychiatry

Volumn 65, Issue 9, 2004, Pages 1197-1210

  Aman, Michael G ^a   Gharabawi, Georges M ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ATTENTION DEFICIT DISORDER; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; COMORBIDITY; CONSENSUS DEVELOPMENT; DEVELOPMENTAL DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION; EXTRAPYRAMIDAL SYNDROME; HUMAN; MENTAL DEFICIENCY; MENTAL DISEASE; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REVIEW;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; BASAL GANGLIA DISEASES; CHILD; CLINICAL TRIALS; COMORBIDITY; CONSENSUS DEVELOPMENT CONFERENCES; DEVELOPMENTAL DISABILITIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MENTAL DISORDERS; MENTAL RETARDATION; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE;

EID: 5444233649     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0907     Document Type: Review

References (70)

1. Borthwick-Duffy SA. Epidemiology and psychopathology in people with mental retardation. J Consult Clin Psychol 1994;62:17-27 (Pubitemid 24058691)
2. Rutter M, Tizard J, Yule W, et al. Isle of Wight studies, 1964-1974. Psychol Med 1976;6:313-332
3. Rush AJ, Frances A. Treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard 2000;105:159-228 (Pubitemid 30415602)
4. Reiss S. Prevalence of dual diagnosis in community-based day programs in the Chicago area. Am J Ment Retard 1990;6:578-585 (Pubitemid 20172211)
5. Aman MG. Assessing Psychopathology and Behavior Problems in Persons with Mental Retardation: A Review of Available Instruments. Department Human Services publication (ADM) 91-1712. Rockville, Md: US Dept Health Human Services; 1991
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
7. Benson BA. Behavior disorders and mental retardation: associations with age, sex, and level of functioning in an outpatient clinic sample. Appl Res Ment Retard 1985;6:79-85 (Pubitemid 16159075)
8. Rinck D. Epidemiology and psychoactive medication. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, Ohio: The Ohio State University Nisonger Center; 1998:31-44
9. Lund J. Treatment of psychiatric morbidity in the mentally disabled adult. Acta Psychiatr Scand 1983;73:429-436
10. Spreat S, Conroy JW, Jones JC. Use of psychotropic medication in Oklahoma: a statewide survey. Am J Ment Retard 1997;102:80-85 (Pubitemid 27334712)
11. Alfredsson G, Härnryd C, Wiesel FA. Effects of sulpiride and chlorpromazine on autistic and positive psychotic symptoms in schizophrenic patients' relationship to drug concentrations. Psychopharmacology (Berl) 1985;85:8-13 (Pubitemid 15159589)
12. Craft MJ, Schiff AA. Psychiatric disturbance in mentally handicapped patients. Br J Psychiatry 1980;137:250-255
13. Sajatovic M, Ramirez LF, Kenny JT, et al. The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Compr Psychiatry 1994;35:29-33 (Pubitemid 24040038)
14. Menolascino FJ, Ruedrich SL, Golden GJ, et al. Diagnosis and pharmacotherapy of schizophrenia in the retarded. Psychopharmacol Bull 1985; 21:316-322 (Pubitemid 15114536)
15. Baumeister AA, Sevin JA, King BH. Neuroleptics. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, Ohio: The Ohio State University Nisonger Center; 1998:133-150
16. Aman MG, Madrid A. Atypical antipsychotics in persons with developmental disabilities. MRDD Res Rev 1999;5:253-263 (Pubitemid 30033613)
17. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137 (Pubitemid 27240346)
18. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999;60(suppl 10):20-30 (Pubitemid 29237172)
19. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39
20. Shapiro DA, Renock S, Arlington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411 (Pubitemid 41070874)
21. Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 2001;62(suppl 15):12-17 (Pubitemid 32601343)
22. Simon EW, Blubaugh KM, Pippidis M. Substituting traditional antipsychotics with risperidone for people with mental retardation. Ment Retard 1996;34:359-366 (Pubitemid 26424423)
23. Kalachnik JE, Leventhal BL, James DH, et al. Guidelines for the use of psychotropic medication. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, Ohio: The Ohio State University Nisonger Center; 1998:45-72
24. Matson JL, Bamburg JW, Mayville EA, et al. Psychopharmacology and mental retardation: a 10-year review (1990-1999). Res Dev Disabil 2000;21:263-296
25. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment affects. Am J Ment Defic 1985;89:485-491 (Pubitemid 15104762)
26. Conners CK. Sitarenios G, Parker JDA, et al. Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998;26: 279-291 (Pubitemid 28359776)
27. Conners CK, Sitarenios G, Parker JDA, et al. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998;26:257-268 (Pubitemid 28359774)
28. Guy W. Clinical Global Impressions Scale. In: Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000
29. Achenbach, TM, Ruffle TM. The Child Behavior Checklist and related forms for assessing behavior/emotional problems and competencies. Pediatr Rev 2000;21:265-271
30. Reiss S. 1988 Reiss Screen for Maladaptive Behavior. Orland Park, Ill: International Diagnostic Systems, Inc; 1988
31. Aman MG, Tasse MJ, Rojahn J, et al. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil 1996;17:41-57 (Pubitemid 26030823)
32. Matson JL, Gardner WI, Coe DA, et al. A scale for evaluating emotional disorders in severely and profoundly mentally retarded persons: development of the Diagnostic Assessment for the Severely Handicapped (DASH) scale. Br J Psychiatry 1991;159:404-409
33. Kemner C, Willemsen-Swinkels SHN, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22:455-460
34. Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry 2003; 64:1258-1265
35. Aman MG, De Smedt G, Derivan A, et al., and the Risperidone Disruptive Behavior Study Group. Risperidone treatment of children with disruptive behavior symptoms and subaverage IQ: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159:1337-1346
36. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41:1026-1036 (Pubitemid 38338050)
37. Findling RL, Aman MG, Eerdekens M, et al., and the Risperidone Disruptive Behavior Study Group. Long-term open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004;161:677-684
38. Findling RL, Fegert JM, De Smedt G, on behalf of the International Disruptive Behavior Study Group. Risperidone in children and adolescents with severe disruptive behaviors and subaverage IQ. In: Program and Abstracts of the 40th American College of Neuropsychopharmacology Annual Meeting; Dec 9-13, 2001; Waikoloa, Hawaii
39. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321
40. De Smedt G, Gagiano CA, Read S, et al. Efficacy of risperidone in the treatment of behavioral disturbances in adults with subaverage IQ. In: Program and Abstracts of the 23rd Collegium Internationale NeuroPsychopharmacologicum Annual Meeting; June 23-27, 2002; Montreal, Quebec, Canada. Poster P4.E.093
41. Gagiano C, Read S, Thorpe L, et al. Behavioral disturbances in adults with conduct spectrum disorders and subaverage IQ: a double-blind study of risperidone vs placebo. In: Program and Abstracts of the Association of European Psychiatrists Annual Meeting; May 4-8, 2000; Stockholm, Sweden
42. De Smedt G, Gagiano CA, Read S, et al. Risperidone in adults with disruptive behaviour disorders. Presented at the 22nd Congress of the World Psychiatric Association (WPA); Aug 23-29, 2002; Yokohama, Japan
43. Cohen S, Fitzgerald B, Okos A, et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 2003;64:60-62 (Pubitemid 36182231)
44. Cohen SA, Fitzgerald BJ, Kahn SRF, et al. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic open-label treatment. J Clin Psychiatry 2004;65:110-113
45. 2 receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001;158:360-369 (Pubitemid 32205190)
46. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
47. Thorner MO, Vance ML, Horvath E, et al. The anterior pituitary. In: Wilson JD, Foster DW, eds. Williams' Textbook of Endocrinology. 8th ed. Philadelphia, Pa: WB Saunders Co.; 1992:222-224
48. Peuskens J, ed. Clear Perspectives: Management Issues in Schizophrenia. London, United Kingdom: Franklin Scientific Projects Ltd; 1997:1-45
49. De Smedt G, Gagiano CA, Read S, et al. Adults with disruptive behavior disorders (DBDs) and sub-average IQ: safety of risperidone. In: Program and Abstracts of the 23rd Collegium Internationale NeuroPsychopharmacologicum Annual Meeting; June 23-27, 2002: Montreal, Quebec, Canada. Poster R4.E.094
50. Hamill PVV, Drizd TA, Johnson CL, et al. Physical growth: National Center for Health Statistics Percentiles. Am J Clin Nutr 1979;32: 607-629 (Pubitemid 9134950)
51. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000;101:416-432 (Pubitemid 30365564)
52. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001; 15:537-551 (Pubitemid 32735379)
53. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(suppl 23):5-12 (Pubitemid 32952689)
54. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001;24:59-73 (Pubitemid 32113367)
55. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28(suppl 1):83-96 (Pubitemid 36015663)
56. Stigler KA, Potenza MN, Posey DJ, et al. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs 2004;6:33-44 (Pubitemid 38295123)
57. Baptista T, Zarate J, Joober R, et al. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004;5:279-299 (Pubitemid 38372313)
58. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64 (Pubitemid 34538833)
59. Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-723 (Pubitemid 38471372)
60. Matson JL, Bamburg JW. Reliability of the Assessment of Dual Diagnosis (ADD). Res Dev Disabil 1998;19:89-95 (Pubitemid 28086423)
61. Risperdal (risperidone). Physician's Desk Reference. Montvale, NJ: Medical Economics; 2002:1796-1800
62. DeVane CL, Nemeroff CB. An evaluation of risperidone drug interactions. J Clin Psychopharmacol 2001;21:408-416 (Pubitemid 32673030)
63. Sproule BA, Naranjo CA, Brenmer KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-471 (Pubitemid 28014515)
64. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000;22:481-485 (Pubitemid 30622123)
65. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(suppl 3):S80-S88 (Pubitemid 23336512)
66. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001;22:223-227 (Pubitemid 32476548)
67. Jover F, Cuadrado JM, Andreu L, et al. Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol 2002;25: 251-253 (Pubitemid 35239481)
68. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002;43 (suppl 2):37-44 (Pubitemid 34229485)
69. Chouinard G, Ross-Chouinard A, Annable L, et al. The Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980;7:233
70. Matson JL, Kazdin AE, Senatore V. Psychometric properties of the Psychopathology Inventory for Mentally Retarded Adults. Appl Res Ment Retard 1984;5:881-889